Discharge of the asthmatic patient

B. A. Markoff, John MacMillan Jr, V. Kumra

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Asthma continues to be a challenging disease to treat in both the inpatient and outpatient settings. The growing database on therapeutic interventions at the time of transition from the acute to chronic phase of this disease is encouraging. Glucocorticoids and inhaled β-agonists clearly reduce readmission and relapse. other medications and educational interventions also appear effective. Still, no true discharge guidelines have been established. Multiple statements by consensus panels have recommended using FEV1 or PEFR as indicators of readiness for discharge, but this has not been prospectively validated from either the emergency department or patient setting. In contrast, some studies argue that pulmonary function do not accurately predict relapse and readmission, so the usefulness of these discharge recommendations is debatable. Large studies, especially in the adult asthmatic population, are needed to validate these recommendation.

Original languageEnglish (US)
Pages (from-to)341-355
Number of pages15
JournalClinical Reviews in Allergy and Immunology
Volume20
Issue number3
DOIs
StatePublished - 2001

Fingerprint

Patient Discharge
Peak Expiratory Flow Rate
Recurrence
Glucocorticoids
Hospital Emergency Service
Inpatients
Chronic Disease
Outpatients
Asthma
Databases
Guidelines
Lung
Population
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Discharge of the asthmatic patient. / Markoff, B. A.; MacMillan Jr, John; Kumra, V.

In: Clinical Reviews in Allergy and Immunology, Vol. 20, No. 3, 2001, p. 341-355.

Research output: Contribution to journalArticle

Markoff, B. A. ; MacMillan Jr, John ; Kumra, V. / Discharge of the asthmatic patient. In: Clinical Reviews in Allergy and Immunology. 2001 ; Vol. 20, No. 3. pp. 341-355.
@article{01b180fe621741de8f6c00ec2f8716d6,
title = "Discharge of the asthmatic patient",
abstract = "Asthma continues to be a challenging disease to treat in both the inpatient and outpatient settings. The growing database on therapeutic interventions at the time of transition from the acute to chronic phase of this disease is encouraging. Glucocorticoids and inhaled β-agonists clearly reduce readmission and relapse. other medications and educational interventions also appear effective. Still, no true discharge guidelines have been established. Multiple statements by consensus panels have recommended using FEV1 or PEFR as indicators of readiness for discharge, but this has not been prospectively validated from either the emergency department or patient setting. In contrast, some studies argue that pulmonary function do not accurately predict relapse and readmission, so the usefulness of these discharge recommendations is debatable. Large studies, especially in the adult asthmatic population, are needed to validate these recommendation.",
author = "Markoff, {B. A.} and {MacMillan Jr}, John and V. Kumra",
year = "2001",
doi = "10.1385/CRIAI:20:3:341",
language = "English (US)",
volume = "20",
pages = "341--355",
journal = "Clinical Reviews in Allergy and Immunology",
issn = "1080-0549",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - Discharge of the asthmatic patient

AU - Markoff, B. A.

AU - MacMillan Jr, John

AU - Kumra, V.

PY - 2001

Y1 - 2001

N2 - Asthma continues to be a challenging disease to treat in both the inpatient and outpatient settings. The growing database on therapeutic interventions at the time of transition from the acute to chronic phase of this disease is encouraging. Glucocorticoids and inhaled β-agonists clearly reduce readmission and relapse. other medications and educational interventions also appear effective. Still, no true discharge guidelines have been established. Multiple statements by consensus panels have recommended using FEV1 or PEFR as indicators of readiness for discharge, but this has not been prospectively validated from either the emergency department or patient setting. In contrast, some studies argue that pulmonary function do not accurately predict relapse and readmission, so the usefulness of these discharge recommendations is debatable. Large studies, especially in the adult asthmatic population, are needed to validate these recommendation.

AB - Asthma continues to be a challenging disease to treat in both the inpatient and outpatient settings. The growing database on therapeutic interventions at the time of transition from the acute to chronic phase of this disease is encouraging. Glucocorticoids and inhaled β-agonists clearly reduce readmission and relapse. other medications and educational interventions also appear effective. Still, no true discharge guidelines have been established. Multiple statements by consensus panels have recommended using FEV1 or PEFR as indicators of readiness for discharge, but this has not been prospectively validated from either the emergency department or patient setting. In contrast, some studies argue that pulmonary function do not accurately predict relapse and readmission, so the usefulness of these discharge recommendations is debatable. Large studies, especially in the adult asthmatic population, are needed to validate these recommendation.

UR - http://www.scopus.com/inward/record.url?scp=0035010069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035010069&partnerID=8YFLogxK

U2 - 10.1385/CRIAI:20:3:341

DO - 10.1385/CRIAI:20:3:341

M3 - Article

C2 - 11413903

AN - SCOPUS:0035010069

VL - 20

SP - 341

EP - 355

JO - Clinical Reviews in Allergy and Immunology

JF - Clinical Reviews in Allergy and Immunology

SN - 1080-0549

IS - 3

ER -